Traws Pharma (NASDAQ:TRAW) Releases Earnings Results, Beats Expectations By $0.03 EPS

Traws Pharma (NASDAQ:TRAW) issued its earnings results on Friday. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.03, FiscalAI reports.

Traws Pharma Trading Up 15.3%

Shares of NASDAQ:TRAW opened at $1.88 on Friday. The firm has a market cap of $19.10 million, a price-to-earnings ratio of 2.03 and a beta of 1.47. Traws Pharma has a 1 year low of $0.99 and a 1 year high of $3.27. The business has a fifty day simple moving average of $1.68 and a 200 day simple moving average of $1.86.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on TRAW shares. Weiss Ratings upgraded Traws Pharma from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Friday, May 1st. LADENBURG THALM/SH SH raised shares of Traws Pharma to a “strong-buy” rating in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Insider Buying and Selling

In other news, major shareholder Orbimed Advisors Llc bought 597,729 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were bought at an average cost of $1.67 per share, with a total value of $998,207.43. Following the transaction, the insider directly owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 14.00% of the stock is owned by company insiders.

Institutional Trading of Traws Pharma

Institutional investors have recently added to or reduced their stakes in the business. State Street Corp bought a new stake in Traws Pharma in the fourth quarter worth $29,000. Two Sigma Investments LP boosted its position in Traws Pharma by 37.1% during the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares during the period. XTX Topco Ltd grew its holdings in Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after purchasing an additional 31,502 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after purchasing an additional 18,213 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Traws Pharma in the fourth quarter worth $175,000. 7.95% of the stock is currently owned by institutional investors and hedge funds.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.